File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1159/000083591
- Scopus: eid_2-s2.0-21844439018
- PMID: 15812152
- WOS: WOS:000228072200003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Pathogenesis of pre-neoplastic lesions of the stomach: Targets for prevention
Title | Pathogenesis of pre-neoplastic lesions of the stomach: Targets for prevention |
---|---|
Authors | |
Keywords | Atrophy Gastric cancer Helicobacter pylori Intestinal metaplasia |
Issue Date | 2004 |
Publisher | S Karger AG. The Journal's web site is located at http://www.karger.com/DDI |
Citation | Digestive Diseases, 2004, v. 22 n. 4, p. 306-312 How to Cite? |
Abstract | Gastric atrophy and intestinal metaplasia are generally considered to be precancerous lesions of the stomach. Chronic Helicobacter pylori infection is one the most important factors in the development of these pre-malignant gastric lesions. In addition to bacterial factors, polymorphisms in the cytokine genes of the host that modulate inflammatory responses are found to have a synergistic effect in the development of gastric cancer as well as pre-neoplastic lesions. Recently, inappropriate activation of the intestine-specific transcription factor like the homeobox gene complex CDX1 and CDX2 are found to be an important contributing factor in the induction of intestinal metaplasia in the stomach. Aberrant expression of cyclooxygenase-2 and epigenetic changes are also frequently detected in pre-neoplastic gastric lesions. One of the most important questions relating to these pre-neoplastic gastric lesions is that whether H. pylori eradication could reverse these changes. However, most controlled studies showed no or just modest improvement in intestinal metaplasia after H. pylori eradication. Further studies should evaluate the role of other chemopreventive agents, particularly cyclooxygenase-2 inhibitor, on regression of pre-neoplastic lesions. Copyright © 2004 S. Karger AG. |
Persistent Identifier | http://hdl.handle.net/10722/162860 |
ISSN | 2023 Impact Factor: 2.0 2023 SCImago Journal Rankings: 0.744 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Leung, WK | en_US |
dc.contributor.author | Sung, JJY | en_US |
dc.date.accessioned | 2012-09-05T05:24:30Z | - |
dc.date.available | 2012-09-05T05:24:30Z | - |
dc.date.issued | 2004 | en_US |
dc.identifier.citation | Digestive Diseases, 2004, v. 22 n. 4, p. 306-312 | en_US |
dc.identifier.issn | 0257-2753 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/162860 | - |
dc.description.abstract | Gastric atrophy and intestinal metaplasia are generally considered to be precancerous lesions of the stomach. Chronic Helicobacter pylori infection is one the most important factors in the development of these pre-malignant gastric lesions. In addition to bacterial factors, polymorphisms in the cytokine genes of the host that modulate inflammatory responses are found to have a synergistic effect in the development of gastric cancer as well as pre-neoplastic lesions. Recently, inappropriate activation of the intestine-specific transcription factor like the homeobox gene complex CDX1 and CDX2 are found to be an important contributing factor in the induction of intestinal metaplasia in the stomach. Aberrant expression of cyclooxygenase-2 and epigenetic changes are also frequently detected in pre-neoplastic gastric lesions. One of the most important questions relating to these pre-neoplastic gastric lesions is that whether H. pylori eradication could reverse these changes. However, most controlled studies showed no or just modest improvement in intestinal metaplasia after H. pylori eradication. Further studies should evaluate the role of other chemopreventive agents, particularly cyclooxygenase-2 inhibitor, on regression of pre-neoplastic lesions. Copyright © 2004 S. Karger AG. | en_US |
dc.language | eng | en_US |
dc.publisher | S Karger AG. The Journal's web site is located at http://www.karger.com/DDI | en_US |
dc.relation.ispartof | Digestive Diseases | en_US |
dc.subject | Atrophy | - |
dc.subject | Gastric cancer | - |
dc.subject | Helicobacter pylori | - |
dc.subject | Intestinal metaplasia | - |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Cyclooxygenase Inhibitors - Therapeutic Use | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Precancerous Conditions - Etiology - Prevention & Control | en_US |
dc.subject.mesh | Risk Factors | en_US |
dc.subject.mesh | Stomach Neoplasms - Etiology - Prevention & Control | en_US |
dc.title | Pathogenesis of pre-neoplastic lesions of the stomach: Targets for prevention | en_US |
dc.type | Article | en_US |
dc.identifier.email | Leung, WK:waikleung@hku.hk | en_US |
dc.identifier.authority | Leung, WK=rp01479 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1159/000083591 | en_US |
dc.identifier.pmid | 15812152 | - |
dc.identifier.scopus | eid_2-s2.0-21844439018 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-21844439018&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 22 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.spage | 306 | en_US |
dc.identifier.epage | 312 | en_US |
dc.identifier.isi | WOS:000228072200003 | - |
dc.publisher.place | Switzerland | en_US |
dc.identifier.scopusauthorid | Leung, WK=7201504523 | en_US |
dc.identifier.scopusauthorid | Sung, JJY=35405352400 | en_US |
dc.identifier.issnl | 0257-2753 | - |